Amedisys, Inc. (AMED) formed double bottom with $49.02 target or 7.00% below today’s $52.71 share price. Amedisys, Inc. (AMED) has $1.79B valuation. The stock increased 0.09% or $0.05 during the last trading session, reaching $52.71. About 172,526 shares traded. Amedisys, Inc. (NASDAQ:AMED) has risen 15.02% since January 1, 2017 and is uptrending. It has underperformed by 1.68% the S&P500.
Hanmi Financial Corporation operates as the holding firm for Hanmi Bank that provides business banking services and products in the United States. The company has market cap of $983.74 million. It offers various deposit products, including noninterest-bearing checking accounts, interest-bearing checking and savings accounts, negotiable order of withdrawal accounts, money market accounts, and certificates of deposit. It has a 17.15 P/E ratio. The firm also provides real estate loans, such as commercial property, construction, and residential property loans; and commercial and industrial loans, which include commercial term loans and commercial lines of credit, as well as various international finance and trade services and products, including letters of credit, and import and export financing.
Since August 8, 2017, it had 0 insider purchases, and 1 sale for $50,000 activity. $50,000 worth of Amedisys, Inc. (NASDAQ:AMED) was sold by Pearce David B. on Tuesday, August 8.
Analysts await Amedisys, Inc. (NASDAQ:AMED) to report earnings on February, 27. They expect $0.59 earnings per share, up 34.09% or $0.15 from last year’s $0.44 per share. AMED’s profit will be $20.02 million for 22.33 P/E if the $0.59 EPS becomes a reality. After $0.56 actual earnings per share reported by Amedisys, Inc. for the previous quarter, Wall Street now forecasts 5.36% EPS growth.
Investors sentiment decreased to 1.71 in Q3 2017. Its down 0.04, from 1.75 in 2017Q2. It dived, as 26 investors sold Amedisys, Inc. shares while 29 reduced holdings. 30 funds opened positions while 64 raised stakes. 31.75 million shares or 5.19% more from 30.18 million shares in 2017Q2 were reported. Metropolitan Life Ny owns 20,191 shares. Quantitative Systematic Strategies Ltd Liability has invested 0.05% in Amedisys, Inc. (NASDAQ:AMED). Deutsche National Bank Ag reported 0% in Amedisys, Inc. (NASDAQ:AMED). Moreover, Copper Rock Capital Ptnrs Ltd has 2.14% invested in Amedisys, Inc. (NASDAQ:AMED) for 575,315 shares. Sei Invs accumulated 0.02% or 91,706 shares. Price T Rowe Assocs Incorporated Md stated it has 13,880 shares. Swiss Comml Bank holds 47,500 shares. Citadel Limited Liability Company, a Illinois-based fund reported 86,077 shares. Royal Bankshares Of Canada stated it has 0% of its portfolio in Amedisys, Inc. (NASDAQ:AMED). Principal Group Incorporated holds 0.01% or 229,259 shares in its portfolio. California-based Los Angeles Cap Equity Rech has invested 0.01% in Amedisys, Inc. (NASDAQ:AMED). New York State Common Retirement Fund holds 49,500 shares. Eaton Vance Management holds 0.03% of its portfolio in Amedisys, Inc. (NASDAQ:AMED) for 202,487 shares. 149,935 are held by Invesco Limited. Credit Suisse Ag stated it has 0% of its portfolio in Amedisys, Inc. (NASDAQ:AMED).
Among 14 analysts covering Amedisys Inc. (NASDAQ:AMED), 6 have Buy rating, 0 Sell and 8 Hold. Therefore 43% are positive. Amedisys Inc. had 36 analyst reports since September 1, 2015 according to SRatingsIntel. Mizuho upgraded Amedisys, Inc. (NASDAQ:AMED) rating on Monday, November 7. Mizuho has “Buy” rating and $47 target. RBC Capital Markets maintained Amedisys, Inc. (NASDAQ:AMED) rating on Monday, July 10. RBC Capital Markets has “Hold” rating and $5600 target. The stock has “Neutral” rating by Robert W. Baird on Friday, November 10. The stock has “Buy” rating by Benchmark on Thursday, November 2. The company was maintained on Thursday, November 9 by RBC Capital Markets. RBC Capital Markets maintained Amedisys, Inc. (NASDAQ:AMED) rating on Sunday, October 22. RBC Capital Markets has “Hold” rating and $56.0 target. The firm has “Hold” rating given on Sunday, November 5 by Robert W. Baird. Mizuho maintained Amedisys, Inc. (NASDAQ:AMED) rating on Wednesday, March 1. Mizuho has “Neutral” rating and $50 target. The firm has “Buy” rating given on Tuesday, January 19 by Mizuho. As per Wednesday, July 26, the company rating was downgraded by Mizuho.
Analysts await Hanmi Financial Corporation (NASDAQ:HAFC) to report earnings on January, 23. They expect $0.47 earnings per share, up 2.17% or $0.01 from last year’s $0.46 per share. HAFC’s profit will be $15.23M for 16.14 P/E if the $0.47 EPS becomes a reality. After $0.46 actual earnings per share reported by Hanmi Financial Corporation for the previous quarter, Wall Street now forecasts 2.17% EPS growth.
Ratings analysis reveals 50% of Hanmi Financial’s analysts are positive. Out of 2 Wall Street analysts rating Hanmi Financial, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. HAFC was included in 2 notes of analysts from October 19, 2016. FBR Capital maintained the stock with “Outperform” rating in Wednesday, October 19 report. The stock of Hanmi Financial Corporation (NASDAQ:HAFC) has “Market Perform” rating given on Wednesday, October 19 by FIG Partners.
Stieven Capital Advisors L.P. holds 1.45% of its portfolio in Hanmi Financial Corporation for 247,005 shares. Investment Counselors Of Maryland Llc owns 613,868 shares or 0.97% of their US portfolio. Moreover, Opus Capital Group Llc has 0.79% invested in the company for 112,791 shares. The Missouri-based Kennedy Capital Management Inc. has invested 0.41% in the stock. Rbf Capital Llc, a California-based fund reported 75,000 shares.
The stock decreased 1.62% or $0.5 during the last trading session, reaching $30.35. About 106,246 shares traded. Hanmi Financial Corporation (HAFC) has risen 19.68% since January 1, 2017 and is uptrending. It has outperformed by 2.98% the S&P500.